Pieris in $10 million collaboration agreement with Allergan
This article was originally published in Scrip
Executive Summary
The German biopharmaceutical company Pieris has signed a collaboration agreement with Allergan to develop treatments for serious ocular disorders based on its anticalin technology. It will receive $10 million up front. Further financial details were not disclosed.